• Thyroid eye disease.

Contraindicated in:

• OB: Pregnancy.

Use Cautiously in:

• Inflammatory bowel disease (may cause exacerbation)
• Diabetes
• Lactation: Safety not established in breastfeeding
• Rep: Women of reproductive potential
• Pedi: Safety and effectiveness not established in children.

Derm: alopecia, dry skin.

EENT: hearing impairment.

Endo: hyperglycemia.

GI: diarrhea, nausea.

MS: muscle spasms.

Neuro: dysgeusia, headache.

Misc: fatigue, infusion reactions.

Drug-Drug:

• None reported.

• Lyophilized powder for injection: 500 mg/vial;

• IV (Adults): 10 mg/kg initially, then 20 mg/kg every 3 wk for 7 additional doses.

Tepezza

• Exact mechanism in thyroid eye disease not fully characterized. Inhibits insulin-like growth factor-1 receptors.

• Reduction in proptosis (eyeball protrusion)

Therapeutic Classification: n/a

Pharmacologic Classification: monoclonal antibodies

Absorption: IV administration results in complete bioavailability.

Distribution: Minimally distributed to extravascular tissues.

Metabolism/Excretion: Metabolized via proteolytic degradation. Excretion pathway not characterized.

Half-life: 20 days.

(plasma concentrations)

• Explain purpose of teprotumumab to patient.
• Advise patient to notify health care professional if symptoms of infusion reaction occur.
• Inform patient of risk of IBD. Instruct patient to notify health care professional immediately if diarrhea, with or without blood or rectal bleeding, associated with abdominal pain or cramping/colic, urgency, tenesmus or incontinence occurs.
• May cause hyperglycemia. If diabetic, Advise patient to discuss with health care professional need to adjust glycemic control measures including medications as appropriate. Encourage compliance with glycemic control.
• Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional immediately if pregnancy is planned or suspected; discontinue teprotumumab if pregnancy occurs. Advise females of reproductive potential to use effective contraception during therapy and for 6 mo following last dose.

TEP-roe-TOOM-ue-mab